Key takeaways for Hawaii
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • Med-QUEST coverage rules apply for Prediabetes patients in Hawaii — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
Hawaii-specific context
Hawaii has telehealth access concentrated in Honolulu, East Honolulu, Pearl City metros, with additional reach to Hilo and Kailua. Queen's Health Systems, Hawaii Pacific Health is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at health.hawaii.gov.
Hawaiitelehealth & pricing rules
- • Hawaii requires a live video consultation before a GLP-1 prescription.
- • Hawaii allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in Hawaii: ~$339/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.